DBV Technologies S.A. (NASDAQ:DBVT) Position Reduced by Vivo Capital LLC

Vivo Capital LLC trimmed its position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) by 97.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,020 shares of the company's stock after selling 1,322,417 shares during the period. Vivo Capital LLC owned approximately 0.16% of DBV Technologies worth $99,000 as of its most recent filing with the Securities & Exchange Commission.

DBV Technologies Stock Down 4.2 %

DBVT traded down $0.37 on Friday, hitting $8.53. 73,375 shares of the company traded hands, compared to its average volume of 363,002. The stock has a market capitalization of $175.48 million, a PE ratio of -1.90 and a beta of -0.08. DBV Technologies S.A. has a 12-month low of $2.20 and a 12-month high of $9.59. The company has a 50 day moving average of $5.82 and a 200-day moving average of $4.44.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last issued its quarterly earnings data on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. The business had revenue of $0.51 million for the quarter. On average, research analysts anticipate that DBV Technologies S.A. will post -7.05 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on DBVT shares. JMP Securities reaffirmed a "market outperform" rating and set a $10.00 target price on shares of DBV Technologies in a report on Friday, January 10th. StockNews.com began coverage on DBV Technologies in a research report on Wednesday. They set a "hold" rating for the company.

DBV Technologies Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.